share_log

Ainos Priced 780,000 Unit Public Offering @$4.25/Unit; Shares Will be Uplisted to NASDAQ; Company Effectuated a 1:15 Reverse Stock Split

Ainos Priced 780,000 Unit Public Offering @$4.25/Unit; Shares Will be Uplisted to NASDAQ; Company Effectuated a 1:15 Reverse Stock Split

Ainos以每股4.25美元的价格定价为78万个单位的公开发行;股票将在纳斯达克上市;公司实施了 1:15 的反向股票拆分
Benzinga Real-time News ·  2022/08/09 18:00

Ainos, Inc. (OTC:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the pricing of its underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants are immediately separable and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market on August 9, 2022, under the symbols "AIMD" and "AIMDW," respectively. Ainos expects to receive gross proceeds of approximately $3.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the Company has effectuated a reverse split of its issued and outstanding common stock at a ratio of 1-for-15. The reverse stock split became effective at 8 p.m., Eastern Time, on August 8, 2022. The share numbers and pricing information in this release are adjusted to reflect the impact of the reverse stock split. Ainos has granted the underwriters a 45-day option to purchase up to an additional 117,000 shares of common stock and/or up to an additional 117,000 warrants at the public offering price to cover over-allotments, if any. The offering is expected to close on August 11, 2022, subject to customary closing conditions. Maxim Group LLC is acting as sole book-running manager for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-manager for the offering.

Ainos, Inc.(场外交易代码:AIMD)(“Ainos”,或 “公司”)是一家多元化的医疗科技公司,专注于开发新型即时检测、低剂量干扰素疗法和合成RNA驱动的预防药物,今天宣布其承销公开发行78万套的定价,公开发行价格为每单位4.25美元。本次发行的每个单位包括一股普通股和一份认股权证,用于以4.25美元的行使价购买一股普通股。普通股和认股权证可立即分开,并将分开发行。普通股和认股权证预计将于2022年8月9日在纳斯达克资本市场开始交易,代码分别为 “AIMD” 和 “AIMDW”。在扣除承保折扣和佣金以及其他估计的发行费用之前,Ainos预计将获得约330万美元的总收益。在本次发行中,公司已按1比15的比例对其已发行和流通的普通股进行了反向拆分。反向股票拆分于美国东部时间2022年8月8日晚上8点生效。本新闻稿中的股票数量和定价信息经过调整,以反映反向股票拆分的影响。Ainos已授予承销商45天的期权,可以按公开发行价格额外购买最多11.7万股普通股和/或最多11.7万份认股权证,以支付超额配股(如果有)。此次发行预计将于2022年8月11日结束,但须遵守惯例成交条件。Maxim Group LLC是本次发行的唯一账面管理人。阿卡迪亚证券有限责任公司旗下的布鲁克林资本市场担任此次发行的联席经理。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发